Orange Book product · Generic (ANDA)
NEOSTIGMINE METHYLSULFATE
NEOSTIGMINE METHYLSULFATE
At a glance
Nov 25, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 25, 2022
3 yr 7 mo ago
Today
Pharmaceutical detail
Active ingredient
NEOSTIGMINE METHYLSULFATE
Strength
5MG/10ML (0.5MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 208230
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of NEOSTIGMINE METHYLSULFATE
- 2018NEOSTIGMINE METHYLSULFATEBrand (NDA)
NDA 203629 · FRESENIUS KABI USA
- 2013BLOXIVERZBrand (NDA)
NDA 204078 · EXELA PHARMA
- 2023NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 213244 · EUGIA PHARMA
- 2023NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 216542 · SAGENT PHARMS INC
- 2022NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 212627 · NIVAGEN PHARMS INC
- 2022NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 216206 · HIKMA
- 2022NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 216291 · DR REDDYS
- 2021NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 210652 · REGCON HOLDINGS
- 2021NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 213074 · CAPLIN
- 2021NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 212804 · MEITHEAL
- 2019NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 212968 · GLAND
- 2019NEOSTIGMINE METHYLSULFATEGeneric (ANDA)
ANDA 212512 · BE PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
